Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Cellectar Biosciences reported positive 12-month follow-up data from the Phase 2b CLOVER WaM study of iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia. The dataset, which meets FDA requests for accelerated approval, demonstrated an 83.6% overall response rate and a median duration of response of 17.8 months. Iopofosine showed strong efficacy in heavily pretreated BTKi-exposed and refractory patients, achieving a major response rate of approximately 64% with a median duration of response of 18.2 months. The safety profile was manageable with no significant bleeding events and low infection rates.
Key figures
- Drug Name
- Iopofosine I 131
- Phase Of Trial
- Phase 2b
- Dcr percent
- 98.2
- Mrr percent
- 61.8
- Orr percent
- 83.6
- Median dor months
- 17.8
- Median pfs months
- 13.5
- Btki subset dor months
- 18.2
- Btki exposed mrr percent
- 64.1
- Btki refractory mrr percent
- 63.6
- Confirmatory study start quarter
- 4Q26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.